Customer publications – B-705
← Return to all publications
J. Yang, C. Zhao, J. Lim, L. Zhao, R. L. Tourneau, Q. Zhang, D. Dobson, S. Joshi, J. Pang, X. Zhang, S. Pal, C. Andreou, H. Zhang, M. F. Kircher, H. Schmitthenner. Structurally symmetric near-infrared fluorophore IRDye78-protein complex enables multimodal cancer imaging
Theranostics, vol. 11, 2021, pp. 2534-2549
Y. Wang, H. Ni, S. Zhou, K. He, Y. Gao, W. Wu, M. Wu, Z. Wu, X. Qiu, Y. Zhou, B. Chen, D. Pan, C. Huang, M. Li, Y. Bian, M. Yang, L. Miao, J. Liu. Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity
Cancer Immunol Immunother, vol. 70, 2021, pp. 365-376
F. Simonetta, I. S. Alam, J. K. Lohmeyer, B. Sahaf, Z. Good, W. Chen, Z. Xiao, T. Hirai, L. Scheller, P. Engels, O. Vermesh, E. Robinson, T. Haywood, A. Sathirachinda, J. Baker, M. B. Malipatlolla, L. M. Schultz, J. Y. Spiegel, J. T. Lee, D. B. Miklos, C. L. Mackall, S. S. Gambhir, R. S. Negrin. Molecular Imaging of Chimeric Antigen Receptor T Cells by ICOS-ImmunoPET
Clin Cancer Res, vol. 27, 2021, pp. 1058-1068
J. Ren, M. Xu, J. Chen, J. Ding, P. Wang, L. Huo, F. Li, Z. Liu. PET imaging facilitates antibody screening for synergistic radioimmunotherapy with a ¹⁷⁷Lu-labeled αPD-L1 antibody
Theranostics, vol. 11, 2021, pp. 304-315
A. Gonzalez-Junca, O. Reiners, L. D. Borrero-Garcia, D. Beckford-Vera, A. A. Lazar, W. Chou, S. Braunstein, H. VanBrocklin, B. L. Franc, M. H. Barcellos-Hoff. Positron Emission Tomography Imaging of Functional Transforming Growth Factor β (TGFβ) Activity and Benefit of TGFβ Inhibition in Irradiated Intracranial Tumors
Int J Radiat Oncol Biol Phys, vol. 109, 2021, pp. 527-539
P. Diebolder, C. Mpoy, J. Scott, T. T. Huynh, R. Fields, D. Spitzer, N. Bandara, B. E. Rogers. Preclinical Evaluation of an Engineered Single-Chain Fragment Variable-Fragment Crystallizable Targeting Human CD44
J Nucl Med, vol. 62, 2021, pp. 137-143
A. Cavaliere, S. Sun, S. Lee, J. Bodner, Z. Li, Y. Huang, S. L. Moores, B. Marquez-Nostra. Development of ⁸⁹ZrDFO-amivantamab bispecific to EGFR and c-MET for PET imaging of triple-negative breast cancer
Eur J Nucl Med Mol Imaging, vol. 48, 2021, pp. 383-394
I. J. G. Burvenich, Y. W. Goh, N. Guo, H. K. Gan, A. Rigopoulos, D. Cao, Z. Liu, U. Ackermann, C. W. Wichmann, A. F. McDonald, N. Huynh, G. J. O\'Keefe, S. J. Gong, F. E. Scott, L. Li, W. Geng, A. Zutshi, Y. Lan, A. M. Scott. Radiolabelling and preclinical characterization of (89)Zr-Df-radiolabelled bispecific anti-PD-L1/TGF-βRII fusion protein bintrafusp alfa
Eur J Nucl Med Mol Imaging, vol. 48, 2021, pp. 3075-3088
Z. Xiao, A. T. Mayer, T. W. Nobashi, S. S. Gambhir. ICOS Is an Indicator of T-cell-Mediated Response to Cancer Immunotherapy
Cancer Res, vol. 80, 2020, pp. 3023-3032
G. A. Ulaner, N. B. Sobol, J. A. O'Donoghue, A. S. Kirov, C. C. Riedl, R. Min, E. Smith, L. M. Carter, S. K. Lyashchenko, J. S. Lewis, C. O. Landgren. CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging
Radiology, vol. 295, 2020, pp. 606-615
R. Tang, A. Zheleznyak, M. Mixdorf, A. Ghai, J. Prior, K. C. L. Black, M. Shokeen, N. Reed, P. Biswas, S. Achilefu. Osteotropic Radiolabeled Nanophotosensitizer for Imaging and Treating Multiple Myeloma
ACS Nano, vol. 14, 2020, pp. 4255-4264
M. L. Senders, A. E. Meerwaldt, M. M. T. van Leent, B. L. Sanchez-Gaytan, J. C. van de Voort, Y. C. Toner, A. Maier, E. D. Klein, N. A. T. Sullivan, A. M. Sofias, H. Groenen, C. Faries, R. S. Oosterwijk, E. M. van Leeuwen, F. Fay, E. Chepurko, T. Reiner, R. Duivenvoorden, L. Zangi, R. M. Dijkhuizen, S. Hak. Probing myeloid cell dynamics in ischaemic heart disease by nanotracer hot-spot imaging
Nat Nanotechnol, vol. 15, 2020, pp. 398-405
P. M. R. Pereira, K. Mandleywala, A. Ragupathi, J. S. Lewis. Acute Statin Treatment Improves Antibody Accumulation in EGFR- and PSMA-Expressing Tumors
Clin Cancer Res, vol. 26, 2020, pp. 6215-6229
E. Peplau, F. De Rose, S. Reder, M. Mittelhäuser, G. Scafetta, M. Schwaiger, W. A. Weber, A. Bartolazzi, A. Skerra, C. D\'Alessandria. Development of a Chimeric Antigen-Binding Fragment Directed Against Human Galectin-3 and Validation as an Immuno-Positron Emission Tomography Tracer for the Sensitive In Vivo Imaging of Thyroid Cancer
Thyroid, vol. 30, 2020, pp. 1314-1326
N. Pandit-Taskar, M. A. Postow, M. D. Hellmann, J. J. Harding, C. A. Barker, J. A. O\'Donoghue, M. Ziolkowska, S. Ruan, S. K. Lyashchenko, F. Tsai, M. Farwell, T. C. Mitchell, R. Korn, W. Le, J. S. Lewis, W. A. Weber, D. Behera, I. Wilson, M. Gordon, A. M. Wu, J. D. Wolchok. First-in-Humans Imaging with ⁸⁹Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting
J Nucl Med, vol. 61, 2020, pp. 512-519
Jacm Goos, A. Cho, L. M. Carter, T. R. Dilling, M. Davydova, K. Mandleywala, S. Puttick, A. Gupta, W. S. Price, J. F. Quinn, M. R. Whittaker, J. S. Lewis, T. P. Davis. Delivery of polymeric nanostars for molecular imaging and endoradiotherapy through the enhanced permeability and retention (EPR) effect
Theranostics, vol. 10, 2020, pp. 567-584
C. Christensen, L. K. Kristensen, M. Z. Alfsen, C. H. Nielsen, A. Kjaer. Quantitative PET imaging of PD-L1 expression in xenograft and syngeneic tumour models using a site-specifically labelled PD-L1 antibody
Eur J Nucl Med Mol Imaging, vol. 47, 2020, pp. 1302-1313
M. Chomet, M. Schreurs, M. Nguyen, B. Howng, R. Villanueva, M. Krimm, O. Vasiljeva, Gams van Dongen, D. J. Vugts. The tumor targeting performance of anti-CD166 Probody drug conjugate CX-2009 and its parental derivatives as monitored by ⁸⁹Zr-immuno-PET in xenograft bearing mice
Theranostics, vol. 10, 2020, pp. 5815-5828
E. Berg, H. Gill, J. Marik, A. Ogasawara, S. Williams, G. van Dongen, D. Vugts, S. R. Cherry, A. F. Tarantal. Total-Body PET and Highly Stable Chelators Together Enable Meaningful ⁸⁹Zr-Antibody PET Studies up to 30 Days After Injection
J Nucl Med, vol. 61, 2020, pp. 453-460
D. R. Beckford Vera, S. D. Fontaine, H. F. VanBrocklin, B. R. Hearn, R. Reid, G. W. Ashley, D. V. Santi, B. Bengsch, T. Ohtani, O. Khan, M. Setty, S. Manne, S. O'Brien, P. F. Gherardini, R. S. Herati, A. C. Huang, K. M. Chang, E. W. Newell, N. Bovenschen, D. Pe'er, S. M. Albelda, E. J. Wherry. PET Imaging of the EPR Effect in Tumor Xenografts Using Small 15 nm Diameter Polyethylene Glycols Labeled with Zirconium-89
Mol Cancer Ther, vol. 19, 2020, pp. 673-679
Z. Yang, Y. Dai, L. Shan, Z. Shen, Z. Wang, B. C. Yung, O. Jacobson, Y. Liu, W. Tang, S. Wang, L. Lin, G. Niu, P. Huang, X. Chen. Tumour microenvironment-responsive semiconducting polymer-based self-assembly nanotheranostics
Nanoscale Horiz, vol. 4, 2019, pp. 426-433
W. Wei, D. Jiang, Z. T. Rosenkrans, T. E. Barnhart, J. W. Engle, Q. Luo, W. Cai. HER2-targeted multimodal imaging of anaplastic thyroid cancer
Am J Cancer Res, vol. 9, 2019, pp. 2413-2427
J. Riegler, H. Gill, A. Ogasawara, M. Hedehus, V. Javinal, J. Oeh, G. Z. Ferl, J. Marik, S. Williams, D. Sampath, J. Schartner, R. A. D. Carano. VCAM-1 Density and Tumor Perfusion Predict T-cell Infiltration and Treatment Response in Preclinical Models
Neoplasia, vol. 21, 2019, pp. 1036-1050
P. M. R. Pereira, K. Mandleywala, A. Ragupathi, L. M. Carter, Jacm Goos, Y. Y. Janjigian, J. S. Lewis. Temporal Modulation of HER2 Membrane Availability Increases Pertuzumab Uptake and Pretargeted Molecular Imaging of Gastric Tumors
J Nucl Med, vol. 60, 2019, pp. 1569-1578
D. N. Pandya, N. B. Bhatt, F. Almaguel, S. Rideout-Danner, H. D. Gage, K. K. Solingapuram Sai, T. J. Wadas. ⁸⁹Zr-Chloride Can Be Used for Immuno-PET Radiochemistry Without Loss of Antigen Reactivity In Vivo
J Nucl Med, vol. 60, 2019, pp. 696-701
C. Lohrmann, E. M. O'Reilly, J. A. O'Donoghue, N. Pandit-Taskar, J. A. Carrasquillo, S. K. Lyashchenko, S. Ruan, R. Teng, W. Scholz, P. W. Maffuid, J. S. Lewis, W. A. Weber. Retooling a Blood-Based Biomarker: Phase I Assessment of the High-Affinity CA19-9 Antibody HuMab-5B1 for Immuno-PET Imaging of Pancreatic Cancer
Clin Cancer Res, vol. 25, 2019, pp. 7014-7023
M. Li, D. Jiang, T. E. Barnhart, T. Cao, J. W. Engle, W. Chen, W. Cai. Immuno-PET imaging of VEGFR-2 expression in prostate cancer with ⁸⁹Zr-labeled ramucirumab
Am J Cancer Res, vol. 9, 2019, pp. 2037-2046
W. G. Lesniak, C. Chu, A. Jablonska, Y. Du, M. G. Pomper, P. Walczak, M. Janowski. A Distinct Advantage to Intraarterial Delivery of ⁸⁹Zr-Bevacizumab in PET Imaging of Mice With and Without Osmotic Opening of the Blood-Brain Barrier
J Nucl Med, vol. 60, 2019, pp. 617-622
W. G. Lesniak, C. Chu, A. Jablonska, B. Behnam Azad, O. Zwaenepoel, M. Zawadzki, A. Lisok, M. G. Pomper, P. Walczak, J. Gettemans, M. Janowski. PET imaging of distinct brain uptake of a nanobody and similarly-sized PAMAM dendrimers after intra-arterial administration
Eur J Nucl Med Mol Imaging, vol. 46, 2019, pp. 1940-1951
H. J. Lee, E. B. Ehlerding, D. Jiang, T. E. Barnhart, T. Cao, W. Wei, C. A. Ferreira, P. Huang, J. W. Engle, W. Cai. Dual-labeled pertuzumab for multimodality image-guided ovarian tumor resection
Am J Cancer Res, vol. 9, 2019, pp. 1454-1468
L. K. Kristensen, C. Fröhlich, C. Christensen, M. C. Melander, T. T. Poulsen, G. R. Galler, J. Lantto, I. D. Horak, M. Kragh, C. H. Nielsen, A. Kjaer. CD4(+) and CD8a(+) PET imaging predicts response to novel PD-1 checkpoint inhibitor: studies of Sym021 in syngeneic mouse cancer models
Theranostics, vol. 9, 2019, pp. 8221-8238
L. K. Kristensen, C. Christensen, M. M. Jensen, B. J. Agnew, C. Schjöth-Frydendahl, A. Kjaer, C. H. Nielsen. Site-specifically labeled ⁸⁹Zr-DFO-trastuzumab improves immuno-reactivity and tumor uptake for immuno-PET in a subcutaneous HER2-positive xenograft mouse model
Theranostics, vol. 9, 2019, pp. 4409-4420
K. E. Henry, M. M. Dacek, T. R. Dilling, J. D. Caen, I. L. Fox, M. J. Evans, J. S. Lewis. A PET Imaging Strategy for Interrogating Target Engagement and Oncogene Status in Pancreatic Cancer
Clin Cancer Res, vol. 25, 2019, pp. 166-176
N. Dmochowska, W. Tieu, M. D. Keller, H. R. Wardill, C. Mavrangelos, M. A. Campaniello, P. Takhar, P. A. Hughes. Immuno-PET of Innate Immune Markers CD11b and IL-1β Detects Inflammation in Murine Colitis
J Nucl Med, vol. 60, 2019, pp. 858-863
D. Chen, Y. Zhou, D. Yang, M. Guan, M. Zhen, W. Lu, M. E. Van Dort, B. D. Ross, C. Wang, C. Shu, H. Hong. Positron Emission Tomography/Magnetic Resonance Imaging of Glioblastoma Using a Functionalized Gadofullerene Nanoparticle
ACS Appl Mater Interfaces, vol. 11, 2019, pp. 21343-21352
J. T. Yoon, M. S. Longtine, B. V. Marquez-Nostra, R. L. Wahl. Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with ⁸⁹Zr in Human Lymphoma Xenografts
J Nucl Med, vol. 59, 2018, pp. 1219-1224
G. A. Ulaner, S. K. Lyashchenko, C. Riedl, S. Ruan, P. B. Zanzonico, D. Lake, K. Jhaveri, B. Zeglis, J. S. Lewis, J. A. O\'Donoghue. First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using ⁸⁹Zr-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients with Breast Cancer
J Nucl Med, vol. 59, 2018, pp. 900-906
W. K. Tsai, K. A. Zettlitz, R. Tavaré, N. Kobayashi, R. E. Reiter, A. M. Wu. Dual-Modality ImmunoPET/Fluorescence Imaging of Prostate Cancer with an Anti-PSCA Cys-Minibody
Theranostics, vol. 8, 2018, pp. 5903-5914
F. Romero Pastrana, J. M. Thompson, M. Heuker, H. Hoekstra, C. A. Dillen, R. V. Ortines, A. G. Ashbaugh, J. E. Pickett, M. D. Linssen, N. M. Bernthal, K. P. Francis, G. Buist, M. van Oosten, G. M. van Dam, D. L. J. Thorek, L. S. Miller, J. M. van Dijl. Noninvasive optical and nuclear imaging of Staphylococcus-specific infection with a human monoclonal antibody-based probe
Virulence, vol. 9, 2018, pp. 262-272
K. E. Mayer, S. Mall, N. Yusufi, D. Gosmann, K. Steiger, L. Russelli, H. O. Bianchi, S. Audehm, R. Wagner, E. Bräunlein, A. Stelzl, F. Bassermann, W. Weichert, W. Weber, M. Schwaiger, C. D\'Alessandria, A. M. Krackhardt. T-cell functionality testing is highly relevant to developing novel immuno-tracers monitoring T cells in the context of immunotherapies and revealed CD7 as an attractive target
Theranostics, vol. 8, 2018, pp. 6070-6087
K. E. Henry, T. R. Dilling, D. Abdel-Atti, K. J. Edwards, M. J. Evans, J. S. Lewis. Noninvasive ⁸⁹Zr-Transferrin PET Shows Improved Tumor Targeting Compared with (18)F-FDG PET in MYC-Overexpressing Human Triple-Negative Breast Cancer
J Nucl Med, vol. 59, 2018, pp. 51-57
H. M. Gibson, B. N. McKnight, A. Malysa, G. Dyson, W. N. Wiesend, C. E. McCarthy, J. Reyes, W. Z. Wei, N. T. Viola-Villegas. IFNγ PET Imaging as a Predictive Tool for Monitoring Response to Tumor Immunotherapy
Cancer Res, vol. 78, 2018, pp. 5706-5717
R. Chekol, V. R. Solomon, E. Alizadeh, W. Bernhard, D. Fisher, W. Hill, K. Barreto, J. F. DeCoteau, A. C. Parada, C. R. Geyer, H. Fonge. ⁸⁹Zr-nimotuzumab for immunoPET imaging of epidermal growth factor receptor I
Oncotarget, vol. 9, 2018, pp. 17117-17132
I. J. G. Burvenich, S. Parakh, F. T. Lee, N. Guo, Z. Liu, H. K. Gan, A. Rigopoulos, G. J. O\'Keefe, S. J. Gong, Y. W. Goh, H. Tochon-Danguy, F. E. Scott, M. Kotsuma, K. Hirotani, G. Senaldi, A. M. Scott. Molecular imaging of T cell co-regulator factor B7-H3 with ⁸⁹Zr-DS-5573a
Theranostics, vol. 8, 2018, pp. 4199-4209